Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders

Carmen Mingorance
Rosalía Rodríguez-Rodríguez
María Luisa Justo
María Álvarez de Sotomayor
María Dolores Herrera
Department of Pharmacology, School of Pharmacy, University of Seville, Seville, Spain

Abstract: Acetyl-L-carnitine (ALC) and propionyl-L-carnitine (PLC) are two naturally occurring carnitine derivates formed by carnitine acetyltransferase. The beneficial cardiovascular effects of ALC and PLC have been extensively evaluated in animals and humans during the last 20 years. For instance, many clinical trials have suggested ALC and PLC as potential strategies in the management of peripheral arterial disease, heart and cerebral ischemia, and congestive heart failure. As a result, several experts have already aimed to revise the clinical evidence supporting the therapeutic use of ALC and PLC. On the basis of their conclusions, our aim was a critical review of the effectiveness of ALC and PLC in the treatment of cardiovascular diseases. Type 2 diabetes mellitus is an independent risk factor for the development of cardiovascular disease. Therefore we also describe recent studies that have addressed the emerging use of ALC and PLC amelioration of the insulin resistant state and its related morbidities.

Keywords: propionyl-L-carnitine, acetyl-L-carnitine, L-carnitine, cardiovascular diseases, insulin resistance

Introduction

L-carnitine (LC) is a non-protein amino acid, which is synthesized in mammals from the essential amino acids lysine and methionine or obtained from dietary sources. Acetyl-L-carnitine (ALC) and propionyl-L-carnitine (PLC) are two naturally occurring carnitine derivates the formation of which is catalyzed by carnitine acetyltransferase (CAT), an enzyme present in mitochondria and peroxisomes and highly expressed in liver and heart tissues.

LC is an essential cofactor of carnitine palmitoyltransferanse 1 (CPT1), allowing fatty acid transport into mitochondria and the incorporation of long chain fatty acids into the β-oxidation cycle to obtain acetyl-CoA. LC not only plays an important role in fatty acid metabolism, but also in glucose metabolism through its role in modulating the intramitochondrial acetyl-CoA/CoA ratio and the pyruvate dehydrogenase complex (PDH) (Figure 1).

Regulation by LC of the supply of energy is especially important in heart tissue. Moreover, cardiovascular diseases, such as heart failure and ischemia, are frequently accompanied by decreased myocardial ATP levels leading to lower mechanical work efficiency. Thus LC and its derivatives have been considered for use in metabolic therapies which may help cardiomycocytes meet their absolute need for ATP, preserve the pulsatile cardiac function, and maintain cell and tissue viability.

Another well recognized physiological role of LC is to increase the efflux of acyl and acetyl groups (such as the acyl-carnitines and acetyl-carnitine, respectively) out of cells
into the plasma, reducing the accumulation of the intermediate products of β-oxidation. Accumulation of these intermediates has been implicated in the development of insulin resistance in heart and skeletal muscle and of heart failure and ischemia. Accordingly, exogenous administration of PLC and ALC may have beneficial effects in the treatment of insulin resistance and cardiovascular diseases, by restoring tissue carnitine of skeletal muscle and myocardium.

The carnitine esters, ALC and PLC, appear to possess significant strengths over L-carnitine itself. Briefly, ALC, thanks to its chemical structure, may have a preferential effect on the brain tissue. As for PLC, its propionyl moiety may replenish one of the intermediates in the citric acid cycle exerting an anaplerotic effect.

The potential therapeutic effects of PLC and ALC in the treatment of cardiovascular diseases have been evaluated since the mid-1980s and over the last decade numerous reviews have already attempted to summarize the experimental and clinical evidence supporting these beneficial cardiovascular effects.

On the other hand, type 2 diabetes mellitus (T2DM) is widely accepted to be an independent risk factor for several cardiovascular disorders: coronary heart disease, stroke, peripheral arterial disease, cardiomyopathy, and congestive heart failure. Interestingly, the most recent data concerning the clinical use of ALC and PLC suggest these LC analogs as potential tools in the management of insulin resistance and T2DM.

In this review, we aim to provide a critical appraisal of the effectiveness of ALC and PLC in the treatment of cardiovascular diseases, and to summarize the emerging findings of studies examining the likely effectiveness of PLC and ALC in the improvement of insulin resistance.

**Therapeutic effects of L-carnitine analogs on cardiovascular diseases**

The cardiovascular effects of L-carnitine and its analogs have already been extensively reviewed by various experts in this field. For that reason, the main aim of this section is to identify points in common between the different reviews rather than summarizing once again data from the original clinical trials.

---

**Figure 1** L-carnitine and energy metabolism.
*Abbreviations:* CPT, carnitine palmitoyl transferase; CRAT, Acetyl-carnitine transferase; CACT, carnitine-acylcarnitine translocase; TCA, tricarboxylic acid.
Peripheral arterial disease

Peripheral arterial disease (PAD) is a clinical manifestation of underlying aorto-iliac and leg atherosclerosis, which is characterized by different degrees of stenosis and obstruction. Intermittent claudication (IC) is the main symptom of PAD and it is defined as cramping leg pain (in the buttocks, thighs, and/or calves) while/after climbing 1 or 2 flights of stairs, or during walking.

The beneficial effects of PLC on PAD, especially in alleviating the IC, have been widely studied, being more relevant than those exerted by LC itself.30 In contrast, the effects of ALC on PAD have been poorly evaluated. Some reviews focused on these effects are the main sources considered in the present analysis.26,27,29

Intermittent claudication is a symptom that profoundly limits the patient's ability to walk and as a result is associated with reduced exercise performance. Thus the primary goal of claudication therapy is to relieve the symptoms during walking and improve exercise performance and community activities.31 In relation to the efficacy of PLC in the treatment of PAD, the authors of these three reviews agreed on highlighting the ability of PLC to improve exercise tolerance in terms of increasing the maximum walking distance (MWD) in patients suffering from IC. This increased MWD has been shown to be independent of the dosage (1–3 g/day), route of administration (intravenous infusion or oral intake), and duration of PLC treatment (short or long term administration) used in the different studies included in the reviews (Table 1).30,32–41

The authors of these reviews emphasized the importance of the clinical trial managed by Brevetti et al33 as the largest study so far, recruiting 485 patients. In this pivotal trial, after 12 months of treatment with 2 g/day of PLC, patients with an initial MWD < 250 m, and randomly allocated to placebo, increased their MWD by 44% vs 61% in the cases receiving the drug (P < 0.055). However, patients with mild functional impairment (MWD > 250 m) showed no response to PLC.33

The reviewers also concluded that PLC seems to be able to improve most measures of quality of life (overall physical activity, pain while walking, and psychological activity) with PLC-treated patients with PAD obtaining better scores than placebo recipients on several different validated questionnaires (namely, the McMaster Health Index Questionnaire [MHIQ], Walking Impairment Questionnaire and the Medical Outcome Study SF-36 Questionnaire). In all the reviews, however, 1 study, focused mainly on assessing the effect of PLC treatment on patient quality of life, was noted as having failed to detect any significant

| Patients(n) | PLC dose | Duration(days) | Route of administration | Diagnosis               | MWD increase PLC | MWD increase Placebo | P value | Quality of life test |
|-------------|----------|---------------|-------------------------|-------------------------|------------------|----------------------|---------|---------------------|
| Brevetti et al33 | 33       | 600 mg/day    | 4 days                 | l.v                     | PAD and IC (Fontaine II) | 20                   | NR                  | P < 0.01 | NR                  |
| Coto et al32     | 282      | 2 g/day       | 180                    | Oral                    | PAD and IC        | 93                   | 35                  | NR           |                    |
| Brevetti et al33 | 214      | 500 mg-3 g/day| 182                    | Oral                    | IC (30 < MWD < 400) | 157                  | 139,571             | 0.026*  | √                   |
|                |          |               |                        |                         | Severe IC (30 < MWD < 250) | 124                 |                     | 0.009* | √                   |
| Brevetti et al33 | 485      | 2 g/day       | 365                    | Oral                    | IC (50 < MWD < 400) | 54                   | 48                  | NS       | x                   |
|                |          |               |                        |                         | Severe IC (30 < MWD < 250) | 87                 | 46                  | P < 0.01* | NR                  |
| Dal Lago et al36| 19       | 3 g/day       | 90                     | Oral                    | Obliterative PAD  | 143.3                | 17.7                | P < 0.05* | NR                  |
| Hiatt et al37    | 155      | 2 g/day       | 180                    | Oral                    | PAD and IC        | 161 seg              | 75 seg              | P < 0.001* | √                   |
| Barker et al38   | 7        | 2 g/day       | 28                     | Oral                    | PAD and IC        | 80 seg               | 0 seg               | NS       | NR                  |
| Ragazzino et al39| 24       | 1, 2 g/day    | 10                     | l.v                     | Diabetic angiopathy (Fontaine IIb) | 30% | NR | P < 0.05* | NR |
| Andreozzi et al39| 42       | 600 mg/day    | 42                     | l.v                     | Moderate IC (MWD < 200) | ≦78.75 | ≦60.09 | P < 0.006* | NR |
|                |          |               |                        |                         | Severe IC (MWD < 100) | ≦107.37 | ≦76.64 | P < 0.0003* | NR |
| Allegra et al41  | 26       | 900 mg/day    | 33                     | l.v                     | Angiopathy (Fontaine III and b) | 157 | NR | P < 0.001* | NR |

Notes: Placebo period in the same group; Placebo group.
Abbreviations: NR, not registered; NS, not statistically significant.
improvements in MHIQ scores in patients with mild claudication treated with PLC.33

One of the symptoms leading to the development of IC is a decreased blood flow in patients with PAD. Wiseman and Brodgen concluded that PLC had no direct vasoactive effects in patients with IC.29 However, other scholars mentioned the capacity of PLC to improve endothelial function,26,42 and some years later, Andreozzi gathered clinical evidence demonstrating the beneficial effects of PLC treatment on the vasculature of patients with PAD.27 More precisely, this recent review concluded that PLC has an ability to enhance flow mediated dilatation (FMD) in the brachial artery,43 even when impaired post-exercise.44 This vasoactive effect of PLC may help to prevent the occurrence of ischemic events in patients with PAD.

Eventually, PAD progresses from IC to ischemic ulcers or gangrene. In this regard, it has been mentioned in some reviews;27,29 many scholars have noted the importance of early studies demonstrating that PLC improved healing of ulcerative trophic lesions in patients with severe chronic obstructive arterial disease.29,45,46

Because patients with claudication are physically impaired, the treatment goals are to relieve symptoms, and improve exercise performance and daily quality of life.31 Consequently, PLC should be considered not only as a potential or emerging candidate, but as a therapeutic approach that is likely to be effective for the treatment of IC in patients with PAD.

Its effectiveness may be enhanced by combining PLC with other strategies, such as exercise training, pulsed muscular compression therapy, or pharmacological treatment with PGE-1.47,48 Accordingly, the latest update of the Inter-Society Consensus for the Management of PAD guidelines (TASC II) included the use of PLC in combination with physical training to improve the symptoms associated with PAD.31 We should also note that, surprisingly, it has recently been reported that the long-term administration of PLC to patients with IC did not result in a statistically significant improvement in peak treadmill performance or quality of life compared with exercise alone.49

Ischemic heart disease
A low carnitine concentration in the heart was observed in patients who died of myocardial infarction,50 so that PLC and ALC may be beneficial in the treatment or in the prevention of damage to the heart after an ischemic insult. In relation to this, the usefulness of LC derivatives in the pharmacological management of the ischemic heart has been strongly supported by research findings in the case of PLC, whereas there is only weak evidence of the effects of ALC on the hypoxic myocardium from isolated rat heart models.31–54

The role of PLC in the human pharmacology of the ischemic heart has already been revised by Arsenian,19 and Lango et al.24 The former and more recent remarked on 2 studies in which PLC demonstrated its beneficial effects in a group of 31 patients with left coronary artery disease treated with a single dose of 15 mg/kg of PLC and in a group of 18 men with stable exertional angina treated with PLC 1.5 mg/day for 30 days, mainly in terms of a reduction in the ST segment depression that is normally observed after an ischemic episode.19,55,56 This reviewer concluded that the function of LC and PLC in ischemic heart disease, though promising, was largely speculative, however. Further, Lango et al in their revision only cited a study where PLC used in doses of 15 mg/kg caused a slight decrease in peripheral resistance in patients with stable coronary disease.24,57

Additional to that found in these reviews, a double-blind, placebo-controlled study carried out with PLC on patients with stable angina showed a reduction of ST segment depression, together with increased total work capacity and prolonged exercise duration and time to ischemic threshold.58 However, the anti-ischemic effects of PLC were less pronounced than those produced by the calcium antagonist diltiazem, PLC being able to reduce ST depression at maximal exercise, but not to increase the time to onset of angina.59

In accordance with the previous reviewers, we should conclude that PLC has interesting protective effects against myocardial ischemia, but that its role in the treatment of this condition is not well established.

Nevertheless, it must be pointed out that intravenous PLC administration prior to coronary artery bypass grafting significantly improved early postoperative recovery in diabetic patients by increasing the cardiac index and reducing pulmonary artery pressure,60 suggesting that PLC may be more effective in preventing ischemic injury, than in treatment of the consequences after an ischemic episode has occurred.

Cerebral ischemia
In contrast to the case of the ischemic heart, the therapeutic effect of ALC on cerebral ischemia has been thoroughly investigated, whereas we are aware of only 1 study of PLC administration, in a rat model of forebrain ischemia.61
Nevertheless, the positive results observed in this study open up new perspectives for the use of PLC in the treatment of neurodegenerative diseases associated with, or secondary to, myocardial ischemia-reperfusion injury and chronic circulatory failure.

Most of the studies focused on the evaluation of the effects of ALC treatment in cerebral ischemic injury did not describe clinical but rather experimental data, which have been review by different experts. These reviews noted that ALC has been reported to improve neurological outcome, prevent free radical-mediated protein oxidation, normalize levels of brain energy metabolites, and decrease lactic acid concentration during early post-ischemia reperfusion. More recently, these findings have been confirmed by Jalal et al who found that pretreatment with ALC (400 mg/kg/day for 5 days) significantly reduced infarct size in focal cerebral ischemia induced using 4 models of middle cerebral artery occlusion in rats.

To date, however, there are insufficient clinical data supporting the use of ALC in damage prevention or treatment of patients with cerebral ischemia. For instance, in a very recent article focused on ALC, only 1 study performed in humans with brain ischemia was mentioned and that had been published back in 1990. In this study, they investigated the effects of ALC on regional cerebral blood flow in 10 male patients with brain ischemia and observed beneficial effects in 8 out of 10 patients 1 hour after IV administration of 1500 mg of ALC.

Considering the great extent of experimental data in the literature that strongly support the beneficial effects of ALC in cerebral ischemia, we note that there is a pressing need for well planned clinical trials considering ALC as a potential pharmacological instrument in patients with brain ischemia.

**Congestive heart failure**

Since PLC and ALC may improve the impaired metabolism of heart muscle, these LC analogs may provide considerable benefits as adjuncts to standard therapy in congestive heart failure (CHF).

Similar to the effects observed in the cardiovascular conditions described above, the effectiveness of PLC in the clinical management of CHF has been more widely discussed than the use of ALC. Indeed, the effects of ALC on heart failure are only indirectly suggested by 2 studies, one performed in patients with heart failure secondary to circulatory shock and the other in patients with coronary artery disease, which is one of the main causes for development of CHF. In the former, 115 patients with circulatory and septic shock received ALC infusion for 12 hours with a previous single bolus intravenously. The results showed a good response to the drug in terms of blood oxygenation during the course of sepsis and heart failure. In the latter, 36 subjects with stable coronary artery disease received 500 mg oral ALC and 200 mg oral α-lipoic acid twice daily and their effect on vascular function and blood pressure were assessed. The trial consisted of two 8-week treatment periods separated by a 4-week washout period, after which subjects were crossed over to the other group. The combined treatment increased brachial artery diameter by 2% to 3% and decreased systolic blood pressure by an average of 9 mm Hg, compared with placebo.

The ability of PLC treatment to improve CHF was reviewed by Ferrari et al in 1997 and 2004. The authors concluded that both acute and chronic administration of PLC improved exercise capacity in patients with moderate and severe CHF (New York Heart Association classes II-IV), occurring in the absence of major hemodynamic and neuroendocrine changes, but were associated with an improved skeletal muscle metabolism, and were likely to decrease levels of the tumor necrosis factor-α, a proinflammatory soluble receptor that is elevated in CHF.

Comparing the two reviews, only slight progress seems to have been made over the 7 years that elapsed between them in the clinical evidence supporting the use of PLC in CHF. Moreover, Ferrari et al also remarked on the importance of a multicenter and international study in which only a slight non-significant difference on exercise test duration was detected. That study found that only in a subgroup of patients, with an ejection fraction of 30% to 40% and with relatively well preserved myocardial function, were results in the exercise duration test enhanced significantly after PLC treatment.

Consequently, we can conclude that the clinical effectiveness of PLC in the treatment of CHF is not well established.

**L-carnitine analogs in diabetes mellitus in clinical practice**

Patients with type 1 or type 2 diabetes are at high risk of various cardiovascular disorders: coronary heart disease, stroke, peripheral arterial disease, cardiomyopathy, and congestive heart failure. Indeed, cardiovascular complications have been identified as the leading causes of diabetes-related morbidity and mortality.

Accumulation of fatty acids and lipid metabolites (such as long chain acyl CoA, diacylglycerol, triacylglycerol, and/or ceramide) has been reported to alter the insulin action
pathway and consequently can be considered as a likely mechanism for the development of insulin resistance in heart and skeletal muscles, probably through the activation of proinflammatory pathways. LC plays an important role in the efflux of these intermediates from the cell and may also be decreasing their accumulation by inhibiting the transport of long chain free fatty acids into the cell. In fact, a connection between LC and CPT1 inhibition through an increase of the malonyl-CoA levels has been suggested. For these reasons, LC and its derivatives may act in various ways to improve insulin resistance.

LC improved insulin-mediated glucose disposal has been demonstrated in both healthy subjects and in patients with T2DM. Since either LC or its derivatives play an important role in fatty acid and glucose oxidation, and both have been found to be altered in T2DM, it can reasonably be hypothesized that PLC and ALC would have beneficial effects in T2DM.

For instance, the first report showing the anti-diabetic effect of ALC was published by Giancaterini et al 10 years ago. On different days, 18 T2DM patients received both a primed-constant infusion of ALC (5 mg/kg body weight priming bolus and either 0.025, 0.1, or 1.0 mg/kg body weight/min constant infusion) and a comparable placebo formulation. Tissue glucose uptake was significantly increased by the administration of ALC, in a dose-dependent manner, and was related to increased glucose storage rather than increased glucose oxidation.

More recently, new data continue to point to the likely effectiveness of ALC administration in the clinical management of T2DM. Bloomer et al conducted a double-blind clinical trial in which pre-diabetic men and women (with fasting blood glucose: 100–125 mg/dL) were randomly assigned either 3 g/day of ALC or placebo for 8 weeks, resulting in slight improvements in fasting glucose, HbA1c and HOMA-IR after ALC treatment. Further, when ALC was administered chronically for 24 weeks to 36 non-diabetic patients (2 g/day) with insulin resistance and hypertension at increased risk of cardiovascular disease, the treatment resulted in an increased glucose disposal rate and improved glucose tolerance in PLC-treated patients. Additionally, higher values of glucose disposal rate were accompanied by higher decreases of systolic blood pressure. The results of this pilot study may provide the basis on which to set up randomized, double-blind clinical trials to formally test the effects of ALC compared with placebo on blood pressure and metabolic profile in T2DM and hypertensive patients.

Finally, it should be mentioned that the effects of PLC on insulin resistance have been reported for the first time following a recent study performed in an animal model of obesity and insulin resistance, the fatty Zucker rat. Chronic administration of oral PLC decreased the body-weight gain, food intake, adiposity, insulin serum concentration, HOMA-IR index, and TAG liver content, demonstrating the considerable improvement of the insulin resistance that had occurred in animals receiving PLC.

Conclusion

Although several clinical trials suggest PLC and ALC as potential pharmacological tools targeting cardiovascular pathologies (namely PAD, brain and heart ischemia, and CHF), only the effectiveness of PLC in the management of the IC in the PAD can be remarked. In relation to this, PLC seems to be more effective when it is combined with other strategies, such as exercise training, pulsed muscular compressions or other pharmacological strategies, suggesting a special role of PLC as a coadjuvant tool in the therapy of IC. In contrast, most of the recent studies evaluated the efficacy of ALC in the amelioration of the insulin resistance state. Nevertheless, well designed and larger clinical trials are still necessary to establish more strongly the beneficial effects of the LC analogs in T2DM.

Disclosure

The authors declare no conflicts of interest.

References

1. Rebouche CJ. Carnitine function and requirements during the life cycle. *FASEB J.* 1992;6(15):3379–3386.
2. Demarquoy J, Georges B, Rigault C, Royer MC. Radioisotopic determination of L-carnitine content in foods commonly eaten in Western countries. *Food Chem.* 2004;86:137–142.
3. Zammit VA. Carnitine acyltransferases: functional significance of subcellular distribution and membrane topology. *Prog Lipid Res.* 1999;38(3):199–224.
4. Ferri L, Valente M, Ursini F, et al. Acetyl-carnitine formation and pyruvate oxidation in mitochondria from different rat tissues. *Bull Mol Biol Med.* 1981;6(1–2):16–23.
5. Lysiak W, Lilly K, DiLisa F, Toth PP, Bieber LL. Quantitation of the effect of L-carnitine on the levels of acid-soluble short-chain acyl-CoA and CoASH in rat heart and liver mitochondria. *J Biol Chem.* 1988;263(3):1151–1156.
6. Broderick TL, Quinney HA, Lopaschuk GD. Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart. *J Biol Chem.* 1992;267(6):3758–3763.
7. Broderick TL, Panagakis G, DiDomenico D, et al. L-carnitine improvement of cardiac function is associated with stimulation in glucose but not fatty acid metabolism in carnitine-deficient hearts. *Cardiovasc Res.* 1995;30(5):815–820.
8. Aboguza K, Shivu GN, Ahmed I, Phan TT, Frenneaux MP. The heart metabolism: pathophysiological aspects in ischaemia and heart failure. *Curr Pharm Des.* 2009;15(8):827–835.
9. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. *Ann NY Acad Sci*. 2004;1033:79–91.

10. Revenco D, Morgan JP. Metabolic modulation and cellular therapy of cardiac dysfunction and failure. *J Cell Mol Med*. 2009;13(5):811–825.

11. Anon. Acetyl-L-carnitine. Monograph. *Altern Med Rev*. 2010;15(1):76–83.

12. Chapela SP, Kriguer N, Fernández EH, Stella CA. Involvement of L-carnitine in cellular metabolism: beyond Acyl-CoA transport. *Mini Rev Med Chem*. 2009;9(13):1518–1526.

13. Zhang L, Keung W, Samokhvalov V, Wang W, Lopaschuk GD. Role of fatty acid uptake and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle. *Biochim Biophys Acta*. 2010;1801(1):1–22.

14. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. *Lancet*. 2010;375(9733):2267–2277.

15. Chess DJ, Stanley WC. Role of diet and fuel overabundance in the development and progression of heart failure. *Cardiovasc Res*. 2008;79(2):269–278.

16. Van der Vusse GJ, Prinzen FW, van Bilsen M, Engels W, Reneman RS. Accumulation of lipids and lipid-intermediates in the heart during ischemia. *Basic Res Cardiol*. 1987;82(Suppl 1):157–167.

17. Paulson DJ, Traxler J, Schmidt M, et al. Protection of the ischemic myocardium by L-propionylcarnitine: effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport and fatty acid oxidation. *Cardiovasc Res*. 1986;20:536–541.

18. Paulson DJ, Schmidt MJ, Romens J, Shug AL. Metabolic and physiological differences between zeroflow and low-flow myocardial ischemia: effects of L-acetylcarnitine. *Basic Res Cardio*. 1984;79(5):551–561.

19. Arsenian MA. Carnitine and its derivatives in cardiovascular disease. *Prog Cardiovasc Dis*. 1997;40(3):265–286.

20. Ferrari R, De Giuli F. The propionyl-L-carnitine hypothesis: an alternative to treating heart failure. *J Card Fail*. 1997;3(3):217–224.

21. Retter AS. Carnitine and its role in cardiovascular disease. *Heart Dis*. 1999;1(2):108–113.

22. Calvani M, Arrigoni-Martelli E. Attenuation by acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion. *Int J Tissue React*. 1999;21(1):1–6.

23. Calvani M, Reda E, Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. *Basic Res Cardiol*. 2000;95(2):75–83.

24. Lango R, Smolenski RT, Narkiewicz M, Suchorzewska J, Lysiak-Szydlowska W. Influence of L-carnitine and its derivatives on myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. *Basic Res Cardiol*. 1984;79(5):551–561.

25. Chess DJ, Stanley WC. Role of diet and fuel overabundance in the development and progression of heart failure. *Cardiovasc Res*. 2008;79(2):269–278.

26. Hiatt WR. Carnitine and peripheral arterial disease. *Eur J Vasc Endovasc Surg*. 2009;28(3):253–259.

27. Andreozzi GM, Propionyl-L-carnitine: intermittent claudication and peripheral arterial disease. *Expert Opin Pharmacother*. 2009;10(16):2097–2097.

28. Rosca MG, Lemieux H, Hoppel CL. Mitochondria in the elderly: is acetylcarnitine a rejuvenator? *Adv Drug Deliv Rev*. 2009;61(14):1332–1342.

29. Wiseman LR, Brogden RN. Propionyl-L-carnitine. *Drugs Aging*. 1998;12(3):243–248.

30. Brevetti G, Perna S, Sbabba C, et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. *Eur Heart J*. 1992;13(2):251–255.

31. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *Eur J Vasc Endovasc Surg*. 2007;33(Suppl 1):S1–S75.

32. Coto V, D’Alessandro L, Grattarola G, et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs placebo. *Drugs Exp Clin Res*. 1992;18(1):29–36.

33. Brevetti G, Perna S, Sbabba C, Cartone DV, Condorelli M. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. *J Am Coll Cardiol*. 1995;26(6):1411–1416.

34. Brevetti G, Perna S, Sbabba C, Martone DV, Di Iorio A, Barletta G. Effect of propionyl-L-carnitine on quality of life in intermittent claudication. *Am J Cardiol*. 1997;79(6):777–780.

35. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. *J Am Coll Cardiol*. 1999;34(5):1618–1624.

36. Dal Lago A, De Martini D, Flore R, et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. *Drugs Exp Clin Res*. 1999;25(1):29–36.

37. Hiatt WR. New treatment options in intermittent claudication: the US experience. *Int J Clin Pract Suppl*. 2001;(119):20–27.

38. Barker GA, Green S, Askew CD, Green AA, Walker PJ. Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. *Med Sci Sports Exerc*. 2001;33(9):1415–1422.

39. Ragozzino G, Mattera E, Madrid E, et al. Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial. *Drugs R D*. 2004;5(4):185–190.

40. Andreozzi GM, Leone A, Laudani R, Martin R, Deinitt G, Cataldi V. Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. *Angiology*. 2008;59(1):84–89.

41. Allegra C, Antignani PL, Schachter I, Kovarech A, Messano M, Virmani A. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease. *Ann Vasc Surg*. 2008;22(4):552–558.

42. Cipolla MJ, Niccoloff A, Rebello T, Amato A, Porter JM. Propionyl-L-carnitine dilates human subcutaneous arteries through an endothelium-dependent mechanism. *J Vasc Surg*. 1999;29(6):1097–1103.

43. Loffredo L, Marcocci A, Pignatelli P, et al. Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease. *Eur Heart J*. 2007;28(5):608–612.

44. Silvestro A, Schiano V, Bucur R, et al. Effect of propionylcarnitine on changes in endothelial function and plasma levels of adhesion molecules induced by acute exercise in patients with intermittent claudication. *Angiology*. 2006;57(2):145–154.

45. Pola P, Flore R, Serriechio M, et al. New carnitine derivatives for the therapy of cutaneous ulcers in vasculopathies. *Drugs Exp Clin Res*. 1991;17(5):277–282.

46. Persico G, Amato B, Aprea G, et al. The early effects of intravenous L-propionyl carnitine on ulcerative trophic lesions of the lower limbs in arteriopathic patients: a controlled randomized study. *Drugs Exp Clin Res*. 1995;21(5):187–198.

47. Riccioni C, Saricenna R, Palermo G, et al. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy. *Leriche stage II*. *Int Angiol*. 2008;27(3):253–259.

48. Milio G, Novo G, Genova C, Luigi Almasio P, Novo S, Pinto A. Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1. *Cardios Drugs Ther*. 2009;23(4):301–306.

49. Hiatt WR, Creager MA, Amato A, Brass EP. Effect of Propionyl-L-carnitine on a Background of Monitored Exercise in Patients with Claudication secondary to Peripheral Artery Disease. *J Cardiopulm Rehabil Prev*. 2010. DOI: 10.1097/HCR.0b013e3181f1fd5.

50. Spagnoli LG, Corsi M, Villaschi S, Palmieri G, Maccari F. Myocardial carnitine deficiency in acute myocardial infarction. *Lancet*. 1982;1(8286):1419–1420.
Vascular Health and Risk Management

Publish your work in this journal

Vascular Health and Risk Management is an international, peer-reviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.